1
|
Poizeau F, Maruani A, Staumont-Sallé D, Jouan N, Ly S, Schollhammer M, Reverte M, Dibao-Dina C, Duong TA, Matard B, Penso-Assathiany D, Dupuy A, Carriot M, Seï JF, Corgibet F, Guillot B, Barbarot S, Leducq S, Bertolotti A, Tannous J, Chaby G, Jullien D, Pépin E, Quéreux G, Beylot-Barry M, Chosidow O. Promoting clinical research in community-based practice: Threats and opportunities. Ann Dermatol Venereol 2024; 151:103272. [PMID: 38688174 DOI: 10.1016/j.annder.2024.103272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 12/12/2023] [Accepted: 03/04/2024] [Indexed: 05/02/2024]
Affiliation(s)
- F Poizeau
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, F-35000 Rennes, France.
| | - A Maruani
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CHRU de Tours, Service de Dermatologie, Unité de Dermatologie pédiatrique, 37000 Tours, France; Universités de Tours et de Nantes, Inserm 1246-SPHERE, Nantes, France
| | - D Staumont-Sallé
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CHU Lille, Service de Dermatologie, Univ Lille, INSERM U1286, Lille Inflammation Translational Research Institute (INFINITE) F-59000, Lille, France
| | - N Jouan
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Cabinet de Dermatologie, 29200 Brest, France
| | - S Ly
- Cabinet de Dermatologie, Gradignan, France; Service de Dermatologie, Hôpital St André, Bordeaux, France
| | - M Schollhammer
- Cabinet de Dermatologie, 29200 Brest, France; Service de Dermatologie, CHU Brest, Brest, France
| | - M Reverte
- Cabinet de Dermatologie, 83120 Sainte-Maxime, France
| | - C Dibao-Dina
- Universités de Tours et de Nantes, Inserm 1246-SPHERE, Nantes, France; Département Universitaire de Médecine Générale, Université de Tours, Tours, France
| | - T-A Duong
- Service de dermatologie générale et oncologique, CHU Ambroise Paré, Boulogne-Billancourt, France
| | - B Matard
- Centre Sabouraud, Hôpital Saint Louis, Paris, France
| | | | - A Dupuy
- Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail)-UMR_S 1085, F-35000 Rennes, France
| | - M Carriot
- Infirmière puéricultrice de recherche, CIC 1415 de Tours, Tours, France
| | - J-F Seï
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Fédération Française de Formation Continue et d'Évaluation en Dermatologie Vénéréologie
| | - F Corgibet
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France
| | - B Guillot
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Dermatologue, Université de Montpellier, Montpellier, France
| | - S Barbarot
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Nantes Université, Service de Dermatologie, CHU Nantes, INRAE, UMR 1280, PhAN, F-44000 Nantes, France
| | - S Leducq
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHRU Tours, 37000 Tours, France
| | - A Bertolotti
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; CIC-INSERM1410, Service de Maladies Infectieuses - Dermatologie, CHU de la Réunion, Saint Pierre, La Réunion, France
| | - J Tannous
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France
| | - G Chaby
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Amiens, 80000 Amiens, France
| | - D Jullien
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Hospices Civils de Lyon, Hôpital E. Herriot, Service de Dermatologie, Lyon F-69003; Université Lyon-1, INSERM Unité 1111-CIRI, Lyon F-69007, France
| | - E Pépin
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Dermatologue, FFFCEDV, Villepreux, France
| | - G Quéreux
- Service de Dermatologie, CHU Nantes, Université de Nantes, CIC 1413, Inserm UMR 1302/EMR6001 INCIT, F-44000 Nantes, France
| | - M Beylot-Barry
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; Service de Dermatologie, CHU Bordeaux, INSERM U1312, Bordeaux Institute of Oncology, Univ Bordeaux, Bordeaux, France
| | - O Chosidow
- Centre de Preuves en Dermatologie, Société Française de Dermatologie, 10 Cité Malesherbes, 75009 Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, consultation dermatoses faciales, Paris, France
| |
Collapse
|
2
|
Reguiai Z, Becherel PA, Fougerousse AC, Chaby G, Perrot JL, Begon E, Jacobzone-Lévêque C, Boulard C, Badaoui A, Poreaux C, David L, Quiles-Tsimaratos N, Lons-Danic D, Fite C, Liegeon AL, Patchinsky A, Parier J, Garcia C, Estève E, Mohty R, Mery-Bossard L, Maccari F. Janus kinase inhibitors for the treatment of atopic dermatitis: Real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee recommended measures. J Eur Acad Dermatol Venereol 2023; 37:e1307-e1309. [PMID: 37415328 DOI: 10.1111/jdv.19302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2023] [Accepted: 06/26/2023] [Indexed: 07/08/2023]
Affiliation(s)
- Z Reguiai
- Department of Dermatology, Polyclinique Courlancy, Reims-Bezannes, France
| | - P A Becherel
- Dermatology and Clinical Immunology Unit, Antony Hospital, Antony, France
| | - A C Fougerousse
- Department of Dermatology, Hôpital d'Instruction des Armées Begin, Saint Mandé, France
| | - G Chaby
- Department of Dermatology, CHU Amiens-Picardie, Amiens, France
| | - J L Perrot
- Department of Dermatology, CHU Saint Etienne, Saint Etienne, France
| | - E Begon
- Department of Dermatology, Centre Hospitalier René Dubos, Pontoise, France
| | | | - C Boulard
- Department of Dermatology, Centre Hospitalier Le Havre, Le Havre, France
| | | | - C Poreaux
- Centre de Dermatologie Stanislas, Clinique Pasteur, Nancy, France
| | - L David
- Department of Dermatology, Hopital Saint Joseph, Marseille, France
| | | | - D Lons-Danic
- Department of Dermatology, Hôpital Paris Saint Joseph, Paris, France
| | - C Fite
- Department of Dermatology, Hôpital Paris Saint Joseph, Paris, France
| | - A-L Liegeon
- Department of Dermatology, Centre Hospitalier Régional Metz-Thionville, Thionville, France
| | - A Patchinsky
- Department of Dermatology, Centre Hospitalier Régional Metz-Thionville, Thionville, France
| | - J Parier
- Centre de Santé Sabouraud, Hôpital Saint-Louis, Paris, France
- Cabinet Médical, Saint-Maur-des-Fossés, France
| | - C Garcia
- Department of Dermatology, Centre Hospitalier Emile Roux, Le Puy-en-Velay, France
| | - E Estève
- Department of Dermatology, Centre Hospitalier d'Orléans, Orléans, France
| | - R Mohty
- Cabinet Médical, Beauvais, France
| | - L Mery-Bossard
- Department of Dermatology, CHI Poissy Saint Germain, Saint-Germain-en-Laye, France
| | - F Maccari
- Department of Dermatology, Hôpital d'Instruction des Armées Begin, Saint Mandé, France
- Cabinet Médical, Saint-Maur-des-Fossés, France
| |
Collapse
|
3
|
Guelimi R, Afach S, Régnaux JP, Bettuzzi T, Chaby G, Sbidian E, Naudet F, Le Cleach L. Overlapping network meta-analyses on psoriasis systemic treatments: an overview, quantity does not make quality. Br J Dermatol 2021; 187:29-41. [PMID: 34854074 DOI: 10.1111/bjd.20908] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2021] [Revised: 11/27/2021] [Accepted: 11/28/2021] [Indexed: 11/29/2022]
Abstract
BACKGROUND Network Meta-analyses (NMAs) have become successful in addressing gaps in the comparative effectiveness of systemic treatments in moderate-to-severe psoriasis. However, their increasing number carries both a risk of overlap and reproducibility issues that can hamper clinical decision-making. In this overview, we aimed to assess redundancy across these NMAs and to describe their characteristics. METHODS We considered all systematic reviews with NMAs of randomized controlled trials that included adult patients with moderate-to-severe psoriasis and that evaluated the efficacy and/or safety of systemic treatments compared with placebo or with an active comparator. PubMed/MEDLINE, Epistemonikos, PROSPERO and the Evidence Update of the Centre of Evidence-Based Dermatology of the University of Nottingham were searched up to 25 February 2021. Our main outcome was the number per year of redundant NMAs and the extent of their overlap. We also described their features, especially, the confidence in the results of the reviews, the studies' funding and the presence of spin (a description that overstates efficacy and/or understates harm), reporting issues and methodological characteristics. RESULTS In total, 47 redundant NMAs were included. Only 2/47 (4%) included all available treatments. Both efficacy and safety were evaluated in 14/47 (30%) NMAs and both short and long-term evaluations were assessed in 5/47 (11 %). Confidence in the results was critically low for 39/47 (83%) NMAs and only 10/47 (23 %) registered a protocol. 26/47 NMAs (55%) received pharmaceutical funding. CROs were involved in 19/47 (40%) NMAs. Reporting was poor across most of the NMAs' abstracts and spin was present in all of the abstracts. Almost half of the NMA failed to consider important limitations such as heterogeneity (32%) or consistency (66%). DISCUSSION In addition to a duplication of efforts, our overview showed heterogeneous methods and poor confidence in the results in a majority of the included NMAs, further distorted by reporting issues and spin. Clinicians need to interpret NMAs with caution when looking for the most reliable and comprehensive evidence.
Collapse
Affiliation(s)
- R Guelimi
- EpiDermE EA 7379, Université Paris Est Créteil, F-94010, Créteil, France
| | - S Afach
- EpiDermE EA 7379, Université Paris Est Créteil, F-94010, Créteil, France
| | - J-P Régnaux
- EpiDermE EA 7379, Université Paris Est Créteil, F-94010, Créteil, France.,Ecole des Hautes Etudes en Santé Publique (EHESP), F-35000, Rennes, France
| | - T Bettuzzi
- EpiDermE EA 7379, Université Paris Est Créteil, F-94010, Créteil, France.,Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, F-94010, Créteil, France
| | - G Chaby
- Dermatology Department, Amiens-Picardie University Hospital Center, Amiens, F-80000, France
| | - E Sbidian
- EpiDermE EA 7379, Université Paris Est Créteil, F-94010, Créteil, France.,Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, F-94010, Créteil, France
| | - F Naudet
- CHU Rennes, INSERM CIC 1414 (Centre d'Investigation Clinique de Rennes), University Rennes, Rennes, F-35000, France
| | - L Le Cleach
- EpiDermE EA 7379, Université Paris Est Créteil, F-94010, Créteil, France.,Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, F-94010, Créteil, France
| |
Collapse
|
4
|
Monfort JB, Denamps J, Attencourt C, Lok C, Sevestre H, Chaby G. Early involvement of lymphatic vessels in pathophysiology of morphea. J Eur Acad Dermatol Venereol 2021; 36:e345-e346. [PMID: 34812536 DOI: 10.1111/jdv.17834] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2021] [Revised: 11/04/2021] [Accepted: 11/17/2021] [Indexed: 11/29/2022]
Affiliation(s)
- J B Monfort
- Service de Dermatologie, Hôpital Tenon, Paris, France
| | - J Denamps
- Service de Dermatologie, Université de Picardie Jules Verne, Hôpitaux Universitaires d'Amiens, Hôpital Sud, Amiens, France
| | - C Attencourt
- Service d'Anatomie et Cytologie Pathologiques, Université de Picardie Jules Verne, Hôpitaux Universitaires d'Amiens, Hôpital Nord, Amiens, France
| | - C Lok
- Service de Dermatologie, Université de Picardie Jules Verne, Hôpitaux Universitaires d'Amiens, Hôpital Sud, Amiens, France
| | - H Sevestre
- Service d'Anatomie et Cytologie Pathologiques, Université de Picardie Jules Verne, Hôpitaux Universitaires d'Amiens, Hôpital Nord, Amiens, France
| | - G Chaby
- Service de Dermatologie, Université de Picardie Jules Verne, Hôpitaux Universitaires d'Amiens, Hôpital Sud, Amiens, France
| |
Collapse
|
5
|
Hébert V, Bastos S, Drenovska K, Meijer J, Ingen-Housz-Oro S, Bedane C, Lunardon L, Debarbieux S, Jedlickova H, Caux F, Chaby G, D'Incan M, Feliciani C, Boulard C, Schumacher N, Schmidt E, Roussel A, Richard MA, Gottlieb J, Ferranti V, Guérin O, Bénichou J, Joly P. International multicentre observational study to assess the efficacy and safety of a 0·5 mg kg -1 per day starting dose of oral corticosteroids to treat bullous pemphigoid. Br J Dermatol 2021; 185:1232-1239. [PMID: 34173243 DOI: 10.1111/bjd.20593] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/17/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND European guidelines propose a 0·5 mg kg-1 per day dose of oral prednisone as initial treatment for bullous pemphigoid (BP). We assessed the safety and efficacy of this regimen depending on BP extent and general condition of the patients. METHODS In a prospective international study, we consecutively included all patients diagnosed with BP. Patients received a 0·5 mg kg-1 per day dose of prednisone, which was then gradually tapered 15 days after disease control, with the aim of stopping prednisone or maintaining minimal treatment (0·1 mg kg-1 per day) within 6 months after the start of treatment. The two coprimary endpoints were control of disease activity at day 21 and 1-year overall survival. Disease severity was assessed according to the Bullous Pemphigoid Disease Area Index (BPDAI) score. RESULTS In total, 198 patients were included between 2015 and 2017. The final analysis comprised 190 patients with a mean age of 80·9 (SD 9·1) years. Control of disease activity was achieved at day 21 in 119 patients [62·6%, 95% confidence interval (CI) 55·3-69.5]; 18 of 24 patients (75%, 95% CI 53·3-90·2), 75 of 110 patients (68·8%, 95% CI 59·2-77·3) and 26 of 56 patients (46.4%, 95% CI 33·0-60·3) had mild, moderate and severe BP, respectively (P = 0·0218). A total of 30 patients died during the study. The overall Kaplan-Meier 1-year survival was 82·6% (95% CI 76·3-87·4) corresponding to 90·9%, 83·0% and 80·0% rates in patients with mild, moderate and severe BP, respectively (P = 0·5). Thresholds of 49 points for BPDAI score and 70 points for Karnofsky score yielded maximal Youden index values with respect to disease control at day 21 and 1-year survival, respectively. CONCLUSIONS A 0·5 mg kg-1 per day dose of prednisone is a valuable therapeutic option in patients with mild or moderate BP whose general condition allows them to be autonomous.
Collapse
Affiliation(s)
- V Hébert
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | - S Bastos
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | - K Drenovska
- Department of Dermatology, Medical University of Sofia, Sofia, Bulgaria
| | - J Meijer
- Center for Blistering Diseases, Department of Dermatology, University Medical Center Groningen, Groningen, the Netherlands
| | - S Ingen-Housz-Oro
- Department of Dermatology, Henri Mondor University Hospital, (AP-HP), Creteil, France
| | - C Bedane
- Department of Dermatology, Limoges University Hospital, Limoges, France
| | - L Lunardon
- Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - S Debarbieux
- Department of Dermatology, Hospices Civils de Lyon, Lyon, France
| | - H Jedlickova
- Department of Dermatology, St. Anne's Faculty Hospital, Brno, Czech Republic
| | - F Caux
- Department of Dermatology, Avicenne Hospital, University Paris 13, Bobigny, France
| | - G Chaby
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - M D'Incan
- Department of Dermatology, Clermont-Ferrand University Hospital, Clermont-Ferrand, France
| | - C Feliciani
- Section of Dermatology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
| | - C Boulard
- Department of Dermatology, Monod General Hospital, le Havre, France
| | - N Schumacher
- Department of Dermatology, University of Lübeck, Lübeck, Germany
| | - E Schmidt
- Department of Dermatology, University of Lübeck, Lübeck, Germany.,Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany
| | - A Roussel
- Department of Dermatology, Orleans Hospital, Orléans, France
| | - M A Richard
- Department of Dermatology, Hôpital la Timone, Assistance Publique des Hôpitaux de Marseille, Marseille, France
| | - J Gottlieb
- Department of Dermatology, Saint Louis Hospital, (AP-HP), Paris, France
| | - V Ferranti
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - O Guérin
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - J Bénichou
- Department of Biostatistics, Rouen University Hospital, Rouen, France
| | - P Joly
- Department of Dermatology, Rouen University Hospital, Center for Autoimmune Bullous Diseases, and INSERM U1234, Normandie University, Rouen, France
| | | |
Collapse
|
6
|
Baltazard T, Senet P, Momar D, Picard C, Joachim C, Adas A, Lok C, Chaby G. Evaluation of timolol maleate gel for management of hard-to-heal chronic venous leg ulcers. Phase II randomised-controlled study. Ann Dermatol Venereol 2021; 148:228-232. [PMID: 33551214 DOI: 10.1016/j.annder.2020.11.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 08/27/2020] [Accepted: 11/05/2020] [Indexed: 01/15/2023]
Abstract
BACKGROUND Venous leg ulcers (VLUs) often take a very long time to heal. Timolol maleate has been reported as displaying efficacy in healing of VLUs. OBJECTIVES To evaluate the efficacy of timolol maleate gel in the management of hard-to-heal VLUs and to assess its safety as a topical agent during 12 weeks of use in combination with conventional treatment. METHODS A prospective, phase-II randomised-controlled trial with a sample size based on Fleming's one-stage design (P0=0.25, P1=0.45, alpha=0.1, beta=0.2) was planned. Patients with VLUs present for ≥24 weeks and with ≥50% granulation tissue were included. One drop of sustained-release timolol gel (Timoptol® LP 0.5%, Santen, Tampere, Finland) per 6 cm2 VLU area was applied every 2 days for 12 weeks in timolol-treated patients, as adjuvant therapy to the standard care protocol (interface dressing and multilayer venous compression). Controls received standard care alone. The primary endpoint was to obtain ≥40% reduction in ulcer area at week 12 (W12). RESULTS Forty-three patients were randomised to the study, with 40 receiving at least one treatment and included in the analysis: 21 timolol-treated patients and 19 controls (females: 70%; median age: 72.5 [range 35-93] years). At W12, ≥40% ulcer-area reduction was achieved in 14/21 (67%) timolol-treated patients vs. 6/19 (32%) controls. No serious adverse events occurred. Local wound infections not requiring systemic antibiotics occurred in 5 cases in the timolol group and in one case in the controls. CONCLUSIONS These results support the benefit and safety of using timolol maleate to manage hard-to-heal VLUs, but confirmation is required in a larger multicentre randomised phase-III study.
Collapse
Affiliation(s)
- T Baltazard
- Department of dermatology, university hospital of Amiens Picardy, université Picardie Jules-Verne, 80054 Amiens cedex 1, France
| | - P Senet
- Department of dermatology, allergy and vascular medicine, hôpital Tenon, hôpitaux universitaires Paris-Est, 75970 Paris cedex 20, France
| | - D Momar
- Department of clinical research and innovation, university hospital of Amiens Picardy, université Picardie Jules-Verne, 80054 Amiens cedex 1, France
| | - C Picard
- Department of clinical research and innovation, university hospital of Amiens Picardy, université Picardie Jules-Verne, 80054 Amiens cedex 1, France
| | - C Joachim
- Department of dermatology, university hospital of Amiens Picardy, université Picardie Jules-Verne, 80054 Amiens cedex 1, France
| | - A Adas
- Department of dermatology, university hospital of Amiens Picardy, université Picardie Jules-Verne, 80054 Amiens cedex 1, France
| | - C Lok
- Department of dermatology, university hospital of Amiens Picardy, université Picardie Jules-Verne, 80054 Amiens cedex 1, France
| | - G Chaby
- Department of dermatology, university hospital of Amiens Picardy, université Picardie Jules-Verne, 80054 Amiens cedex 1, France.
| |
Collapse
|
7
|
Halle A, Tesson JR, Lok C, Attencourt C, Chaby G, Arnault JP. Caractéristiques microscopiques des engainements tumoraux péri-nerveux dans les carcinomes épidermoïdes cutanés : impact pronostique (76 patients). Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
8
|
Séméria L, Arnault JP, Dadban A, Cribier B, Poulet C, Attencourt C, Lok C, Chaby G. Porokératose linéaire avec transformation en carcinome épidermoïde de réponse favorable sous pembrolizumab et cisplatine. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
9
|
Beauvillain Q, Dessirier F, Lombart F, Dadban A, Salle V, Morel P, Attencourt C, Lok C, Chaby G. Scléromyxœdème associé à une gammapathie monoclonale traité par lénalidomide et dexaméthasone. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
10
|
Cohen-Sors R, Dubois C, Djeddi DD, Vanrenterghem A, Lombart F, Lok C, Chaby G, Dadban A. Manifestations dermatologiques chez les enfants traités par biothérapie. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
11
|
Badrignans M, Oro S, Chong-Si-Tsaon A, Bagny K, Le Masson G, Attencourt C, Legoupil D, Denamps J, Dubois R, Faiz S, Beltzung F, D’Incan M, Koubaa W, Hammami G, Beltraminelli H, Balme B, Dalle S, Dorel M, Nicolae A, Moustaghfir I, Skrek S, Deschamps T, Chaby G, Ortonne N. Le mycosis fongoïde pustuleux, une forme particulièrement agressive : étude clinicopathologique de 36 cas. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
12
|
Semeria L, Dadban A, Brazier F, Fumery M, Ikoli JF, Arnault JP, Adas A, Dairi M, Lok C, Chaby G. Severe erosive gingivostomatitis in a patient treated by vedolizumab. Dermatol Online J 2020. [DOI: 10.5070/d32610050468] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
|
13
|
Semeria L, Dadban A, Brazier F, Fumery M, Ikoli JF, Arnault JP, Adas A, Dairi M, Lok C, Chaby G. Severe erosive gingivostomatitis in a patient treated by vedolizumab. Dermatol Online J 2020; 26:13030/qt4w21m02k. [PMID: 33147674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2020] [Accepted: 10/27/2020] [Indexed: 06/11/2023] Open
Abstract
Vedolizumab is a humanized monoclonal antibody that binds to the human a4β7 integrin and is approved for use in inflammatory bowel diseases. We describe a patient with severe, refractory erosive gingivostomatitis, which appeared a few days after the first dose of vedolizumab and resolved after discontinuation of the drug. We believe the gingivostomatitis to be a direct side effect of vedolizumab, rather than an extraintestinal manifestation of the underlying inflammatory bowel diseases. The clinicians need to be aware of this adverse event, which could be mistakenly considered as an extraintestinal manifestation of inflammatory bowel diseases.
Collapse
Affiliation(s)
- L Semeria
- Department of Dermatology, Amiens University hospital, Amiens.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Fougerousse AC, Perrussel M, Bécherel PA, Begon E, Pallure V, Zaraa I, Chaby G, Parier J, Kemula M, Mery-Bossard L, Poreaux C, Taieb C, Maccari F, Reguiai Z. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19. J Eur Acad Dermatol Venereol 2020; 34:e676-e679. [PMID: 32564417 PMCID: PMC7323155 DOI: 10.1111/jdv.16761] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 05/18/2020] [Accepted: 05/22/2020] [Indexed: 12/01/2022]
Affiliation(s)
- A-C Fougerousse
- Dermatology Department, Military Teaching Hospital Bégin, Saint Mandé, France
| | - M Perrussel
- Private Practice Auray, Dermatology Department, University Hospital Rennes, Rennes, France
| | - P-A Bécherel
- Dermatology Department, Private Hospital, Antony, France
| | - E Begon
- Dermatology Department, Centre Hospitalier Pontoise, Pontoise, France
| | - V Pallure
- Dermatology Department, Perpignan Hospital, Perpignan, France
| | - I Zaraa
- Dermatology Department, Saint-Joseph Hospital, Paris, France
| | - G Chaby
- Dermatology Department, University Hospital, Amiens, France
| | - J Parier
- Private Practice, La Varenne Saint Hilaire, France.,Dermatology Department, Saint Louis Hospital, Paris, France
| | - M Kemula
- Private Practice, Paris, France.,Dermatology Department, Tarnier Hospital, Paris, France
| | - L Mery-Bossard
- Dermatology Department, Centre Hospitalier Intercommunal Poissy-Saint Germain en Laye, Poissy, France
| | - C Poreaux
- Private Practice, Nancy, Pasteur Clinic, Essey-les-Nancy, France
| | - C Taieb
- Emma Clinic, Fontenay sous Bois, France
| | - F Maccari
- Dermatology Department, Military Teaching Hospital Bégin, Saint Mandé, France.,Private Practice, La Varenne Saint Hilaire, France
| | - Z Reguiai
- Dermatology Department, Courlancy Polyclinic, Reims-Bezannes, France
| | | |
Collapse
|
15
|
Fougerousse A, Ghislain P, Reguiai Z, Maccari F, Parier J, Bouilly Auvray D, Chaby G, Pallure V, Schmutz J, Clément C, Jacobzone C, Begon E, Esteve E. Effectiveness and short‐term (16‐week) tolerance of guselkumab for psoriasis under real‐life conditions: a retrospective multicenter study. J Eur Acad Dermatol Venereol 2020; 34:e644-e646. [DOI: 10.1111/jdv.16511] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2020] [Accepted: 04/10/2020] [Indexed: 12/28/2022]
Affiliation(s)
- A.‐C. Fougerousse
- Dermatology Department Military Teaching Hospital Bégin St Mandé France
| | - P.‐D. Ghislain
- Dermatology Department Private Practice St‐Luc University Hospital BruxellesMons Belgium
| | - Z. Reguiai
- Dermatology Department Courlancy Polyclinic Reims France
| | | | | | | | - G. Chaby
- Dermatology Department University Hospital Amiens France
| | - V. Pallure
- Dermatology Department Perpignan Hospital Perpignan France
| | - J.‐L. Schmutz
- Dermatology Department University Hospital Brabois Vandoeuvre les Nancy France
| | - C. Clément
- Dermatology Department University Hospital of Côte de Nacre Caen France
| | - C. Jacobzone
- Dermatology Department University Hospital of Lorient Lorient France
| | - E. Begon
- Dermatology Department Pontoise Hospital Pontoise France
| | - E. Esteve
- Dermatology Department Regional Hospital Orléans France
| | | |
Collapse
|
16
|
Amy de la Bretèque M, Beauchet A, Maccari F, Ruer-Mulard M, Bastien M, Chaby G, Le Guyadec T, Estève E, Parier J, Dauendorffer JN, Barthelemy H, Géner G, Wagner L, Pfister P, Bégon E, Mery-Bossard L, Schmutz JL, Mahé E. Les patients psoriasiques vus en cabinet libéral et à l’hôpital sont-ils différents ? Ann Dermatol Venereol 2020; 147:310-312. [DOI: 10.1016/j.annder.2019.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2019] [Accepted: 12/12/2019] [Indexed: 10/25/2022]
|
17
|
Grodner C, Beauchet A, Fougerousse A, Quiles‐Tsimaratos N, Perrot J, Barthelemy H, Parier J, Maccari F, Beneton N, Bouilly‐Auvray D, Ruer‐Mulard M, Boulard C, Jacobzone C, Thomas‐Beaulieu D, Pourchot D, Méry‐Bossard L, Chaby G, Girard C, Duval‐Modeste A, Vermersch‐Langlin A, Delaunay J, Marc S, Kemula M, Steff M, Bilan P, Liégeon A, Aubert H, Solyga B, Kluger N, Mahé E. Tattoo complications in treated and non‐treated psoriatic patients. J Eur Acad Dermatol Venereol 2020; 34:888-896. [DOI: 10.1111/jdv.15975] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 09/04/2019] [Indexed: 11/27/2022]
Affiliation(s)
- C. Grodner
- Dermatology Department Hôpital Victor Dupouy Argenteuil France
| | - A. Beauchet
- Public Health Department Hôpital Ambroise Paré Boulogne‐Billancourt France
| | - A.‐C. Fougerousse
- Dermatology Department Hôpital d'Instruction des Armées Bégin Saint Mandé France
| | | | - J.‐L. Perrot
- Dermatology Department CHU Saint‐Etienne Saint‐Etienne France
| | - H. Barthelemy
- Dermatology Department Centre Hospitalier d'Auxerre Auxerre France
| | - J. Parier
- Private Office La Varenne St Hilaire France
| | - F. Maccari
- Private Office La Varenne St Hilaire France
| | - N. Beneton
- Dermatology Department Centre Hospitalier du Mans Le Mans France
| | - D. Bouilly‐Auvray
- Dermatology Department Centre Hospitalier Universitaire de Dijon Dijon France
| | | | - C. Boulard
- Dermatology Department Hôpital Jacques Monod Le Havre Cedex France
| | - C. Jacobzone
- Dermatology Department Centre Hospitalier de Lorient Lorient France
| | - D. Thomas‐Beaulieu
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - D. Pourchot
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - L. Méry‐Bossard
- Dermatology Department Centre Hospitalier Intercommunal de Poissy/Saint‐Germain‐en‐Laye Saint‐Germain‐en‐Laye France
| | - G. Chaby
- Dermatology Department Hôpital Sud Amiens France
| | - C. Girard
- Dermatology Department Centre Hospitalier Universitaire de Montpellier Montpellier France
| | - A.‐B. Duval‐Modeste
- Dermatology Department Centre Hospitalier Universitaire Charles‐Nicolle Rouen France
| | | | | | - S. Marc
- Dermatology Department Hôpital François Quesnay Mantes La Jolie France
| | | | - M. Steff
- Dermatology Department Hôpital Intercommunal Robert‐Ballanger Aulnay‐sous‐Bois France
| | - P. Bilan
- Dermatology Department Hôpital Intercommunal Robert‐Ballanger Aulnay‐sous‐Bois France
| | - A.‐L. Liégeon
- Dermatology Department Hôpital de Valence Valence France
| | - H. Aubert
- Dermatology Department Centre Hospitalier Universitaire de Nantes Nantes France
| | - B. Solyga
- Private Office Fontenay‐sous‐Bois France
| | - N. Kluger
- Dermatology Department, Allergology, and Venereology University of Helsinki and Helsinki University Central Hospital Helsinki Finland
- Dermatology Department Tattoo Consultation Centre Hospitalier Universitaire Bichat‐Claude Bernard Assistance Publique‐Hôpitaux de Paris Paris France
| | - E. Mahé
- Dermatology Department Hôpital Victor Dupouy Argenteuil France
| | | |
Collapse
|
18
|
Bastos S, Hebert V, Vassileva S, Patsatsi A, Meijer J, Quéreux G, Bedane C, Prost-Squarcioni C, Debardieux S, Oro S, Chaby G, D’Incan M, Litrowski N, Boulard C, Lunardon L, Kiritsi D, Jedlickova H, Feliciani C, Roussel A, Kottler D, Plantin P, Richard MA, Friedrichsen L, Abasq C, Duvert Lehembre S, Gottlieb J, Zebrowska A, Hofmann S, Joly P. Efficacité et tolérance de la prednisone à 0,5 mg/kg/j en traitement initial de la pemphigoïde bulleuse. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Fougerousse AC, Reguiai Z, Boulard C, Begon E, Bénéton N, Chaby G, Delaunay J, Barthelemy H, Parier J, Mery-Bossard L, Maccari F, Bastien M, Lons Danic D, Perrot JL, Jacobzone C, Sultan N, Cottencin AC, Samimi M, Monfort JB, Trovato E, Mahe E. Switchs entre anti-IL17 chez 100 patients atteints de psoriasis: étude rétrospective multicentrique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
20
|
Grodner C, Beauchet A, Fougerousse AC, Quiles-Tsimaratos N, Perrot JL, Barthelemy H, Parier J, Maccari F, Bénéton N, Bouilly-Auvray D, Ruer-Mulard M, Boulard C, Jacobzone C, Thomas-Beaulieu D, Méry-Bossard L, Pourchot D, Chaby G, Girard C, Duval-Modeste AB, Vermersch-Langlin A, Delaunay J, Marc S, Kemula M, Sigal ML, Amy de la Breteque M, Steff M, Bilan P, Liégeon AL, Aubert H, Solyga B, Kluger N, Mahé E. Complications des tatouages chez les patients psoriasiques avec ou sans traitements. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
21
|
Semeria L, Dadban A, Brazier F, Fumery M, Ikoli J, Lok C, Chaby G. Gingivostomatite érosive chez un patient traité par védolizumab. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
22
|
Fougerousse AC, Reguiai Z, Maccari F, Parier J, Schmutz JL, Begon E, Chaby G, Bouilly-Auvray D, Pallure V, Beneton N, Monfort JB, Boulard C, Delaunay J, Clément Lepley C, Bastien M, Mery Bossard L, Perrot JL, Jacobzone C, Vermersch A, Esteve E. Profil des patients à l’initiation du guselkumab : étude rétrospective multicentrique. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
23
|
Affiliation(s)
- A Adas
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - J-P Arnault
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - C Attencourt
- Department of Pathology, Amiens University Hospital, Amiens, France
| | - C Lok
- Department of Dermatology, Amiens University Hospital, Amiens, France
| | - G Chaby
- Department of Dermatology, Amiens University Hospital, Amiens, France
| |
Collapse
|
24
|
Dhaille F, Dillies A, Dessirier F, Reygagne P, Diouf M, Balthazard T, Lombart F, Hébert V, Chopinnaud M, Verneuil L, Becquart C, Delaporte E, Lok C, Chaby G. Single typical trichoscopic feature predictive of tinea capitis. Br J Dermatol 2019. [DOI: 10.1111/bjd.18495] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Dhaille F, Dillies A, Dessirier F, Reygagne P, Diouf M, Balthazard T, Lombart F, Hébert V, Chopinnaud M, Verneuil L, Becquart C, Delaporte E, Lok C, Chaby G. 单一典型的毛发镜检特征可预测头癣. Br J Dermatol 2019. [DOI: 10.1111/bjd.18507] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
26
|
Chaby G, Maldini C, Haddad C, Lebrun‐Vignes B, Hemery F, Ingen‐Housz‐Oro S, Gonzalez‐Chiappe S, Wolkenstein P, Chosidow O, Mahr A, Fardet L. Incidence of and mortality from epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) in France during 2003–16: a four‐source capture–recapture estimate. Br J Dermatol 2019; 182:618-624. [DOI: 10.1111/bjd.18424] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/02/2019] [Indexed: 12/14/2022]
Affiliation(s)
- G. Chaby
- EA 7379 EpiDermE Université Paris Est Créteil France
| | - C. Maldini
- Department of Internal Medicine Hôpital Saint Louis, AP‐HP Paris France
| | - C. Haddad
- EA 7379 EpiDermE Université Paris Est Créteil France
- Regional Center of Pharmacovigilance Hôpital Pitié‐Salpêtrière, AP‐HP Paris France
| | - B. Lebrun‐Vignes
- EA 7379 EpiDermE Université Paris Est Créteil France
- Regional Center of Pharmacovigilance Hôpital Pitié‐Salpêtrière, AP‐HP Paris France
| | - F. Hemery
- Department of Medical InformaticsHôpital Henri‐Mondor, AP–HP Créteil France
| | - S. Ingen‐Housz‐Oro
- EA 7379 EpiDermE Université Paris Est Créteil France
- Department of Dermatology and Reference Center for Toxic Bullous Diseases Hôpital Henri‐Mondor, AP–HP Créteil France
| | | | - P. Wolkenstein
- EA 7379 EpiDermE Université Paris Est Créteil France
- Department of Dermatology and Reference Center for Toxic Bullous Diseases Hôpital Henri‐Mondor, AP–HP Créteil France
| | - O. Chosidow
- EA 7379 EpiDermE Université Paris Est Créteil France
- Department of Dermatology and Reference Center for Toxic Bullous Diseases Hôpital Henri‐Mondor, AP–HP Créteil France
- INSERM Centre d'Investigation Clinique 1430 Créteil France
| | - A. Mahr
- Department of Internal Medicine Hôpital Saint Louis, AP‐HP Paris France
| | - L. Fardet
- EA 7379 EpiDermE Université Paris Est Créteil France
- Department of Dermatology and Reference Center for Toxic Bullous Diseases Hôpital Henri‐Mondor, AP–HP Créteil France
| |
Collapse
|
27
|
Dhaille F, Dillies A, Dessirier F, Reygagne P, Diouf M, Baltazard T, Lombart F, Hébert V, Chopinaud M, Verneuil L, Becquart C, Delaporte E, Lok C, Chaby G. A single typical trichoscopic feature is predictive of tinea capitis: a prospective multicentre study. Br J Dermatol 2019; 181:1046-1051. [DOI: 10.1111/bjd.17866] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/04/2019] [Indexed: 12/25/2022]
Affiliation(s)
- F. Dhaille
- Department of Dermatology Amiens University Medical Center AmiensFrance
| | - A.‐S. Dillies
- Department of Dermatology Amiens University Medical Center AmiensFrance
| | - F. Dessirier
- Department of Dermatology Amiens University Medical Center AmiensFrance
| | - P. Reygagne
- Centre Sabouraud Hôpital Saint Louis ParisFrance
| | - M. Diouf
- Biostatistics Department Clinical Research and Innovation Directorate Amiens University Medical Center AmiensFrance
| | - T. Baltazard
- Department of Dermatology Amiens University Medical Center AmiensFrance
| | - F. Lombart
- Department of Dermatology Amiens University Medical Center AmiensFrance
| | - V. Hébert
- Department of Dermatology Rouen University Medical Center RouenFrance
| | - M. Chopinaud
- Department of Dermatology Caen University Medical Center CaenFrance
| | - L. Verneuil
- Department of Dermatology Caen University Medical Center CaenFrance
| | - C. Becquart
- Department of Dermatology Lille University Medical Center Lille France
| | - E. Delaporte
- Department of Dermatology Lille University Medical Center Lille France
| | - C. Lok
- Department of Dermatology Amiens University Medical Center AmiensFrance
| | - G. Chaby
- Department of Dermatology Amiens University Medical Center AmiensFrance
| |
Collapse
|
28
|
Phan C, Beauchet A, Burztejn A, Severino‐Freire M, Barbarot S, Girard C, Lasek A, Reguiai Z, Hadj‐Rabia S, Abasq C, Brenaut E, Droitcourt C, Perrussel M, Mallet S, Phan A, Lacour J, Khemis A, Bourrat E, Chaby G, Deborde R, Plantin P, Maruani A, Piram M, Maccari F, Fougerousse A, Kupfer‐Bessaguet I, Balguérie X, Barthelemy H, Martin L, Quiles‐Tsimaratos N, Mery‐Brossard L, Pallure V, Lons‐Danic D, Bouilly‐Auvray D, Beylot‐Barry M, Puzenat E, Aubin F, Mahé E. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis. J Eur Acad Dermatol Venereol 2019; 33:1984-1992. [DOI: 10.1111/jdv.15579] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2018] [Accepted: 02/27/2019] [Indexed: 02/06/2023]
|
29
|
Dairi M, Dadban A, Arnault J, Lok C, Chaby G. Localized mycosis fungoides treated with laser‐assisted photodynamic therapy: a case series. Clin Exp Dermatol 2019; 44:930-932. [DOI: 10.1111/ced.13936] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/08/2018] [Indexed: 12/01/2022]
Affiliation(s)
- M. Dairi
- Department of Dermatology Amiens University Hospital Amiens France
| | - A. Dadban
- Department of Dermatology Amiens University Hospital Amiens France
| | - J.‐P. Arnault
- Department of Dermatology Amiens University Hospital Amiens France
| | - C. Lok
- Department of Dermatology Amiens University Hospital Amiens France
| | - G. Chaby
- Department of Dermatology Amiens University Hospital Amiens France
| |
Collapse
|
30
|
Dubois C, Dadban A, Denamps J, Arnault JP, Lok C, Chaby G. Congenital melanocytic naevus and congenital strabismus. Clin Exp Dermatol 2019; 44:213-214. [DOI: 10.1111/ced.13622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/27/2017] [Indexed: 11/27/2022]
Affiliation(s)
- C. Dubois
- Department of Dermatology; Amiens University Hospital; Amiens France
| | - A. Dadban
- Department of Dermatology; Amiens University Hospital; Amiens France
| | - J. Denamps
- Department of Dermatology; Amiens University Hospital; Amiens France
| | - J. P. Arnault
- Department of Dermatology; Amiens University Hospital; Amiens France
| | - C. Lok
- Department of Dermatology; Amiens University Hospital; Amiens France
| | - G. Chaby
- Department of Dermatology; Amiens University Hospital; Amiens France
| |
Collapse
|
31
|
Lombart F, Dillies A, Senet P, Pourchot D, Oro S, Modiano P, Barete S, Perceau G, Humbert P, Brault F, Poreaux C, Lorriaux A, Lok C, Chaby G. Calciphylaxie chez des patients non insuffisants rénaux : série de 10 cas. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
32
|
Philibert F, Arnault JP, Adjide C, Baltazard T, Dadban A, Chaby G, Lok C. Gestion d’une épidémie d’Acinetobacter baumanii résistant à l’imipénem (ABRI) dans un service de dermatologie. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
33
|
Dairi M, Arnault JP, Dadban A, Lombart F, Attencourt C, Ortonne N, Lok C, Chaby G. Pseudolymphome cutané en forme de nodules sur des plaques de morphée préexistante. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
34
|
Amy de la Breteque M, Beauchet A, Maccari F, Ruer-Mulard M, Bastien M, Chaby G, Le Guyadec T, Estève E, Parier J, Dauendorffer JN, Barthelemy H, Gener G, Wagner L, Pfister P, Bégon E, Mery-Brossard L, Schmutz JL, Mahé E. Les patients psoriasiques vus en cabinet libéral et à l’hôpital sont-ils différents ? Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
35
|
Joachim-Naepels C, Toubeau G, Attencourt C, Chaby G, Petit T. Proposition d’une classification en stades histopronostiques pour l’hidradénite suppurée à partir d’une série de 172 préparations histologiques. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
36
|
Masmoudi W, Hebert V, Quéreux G, Bedane C, Prost-Squarcioni C, Debarbieux S, Oro S, Chaby G, D’incan M, Litrowski N, Boulard C, Roussel A, Kottler D, Abasq C, Richard MA, Duvert-Lehembre S, Gottlieb J, Plantin P, Joly P. Calcul des valeurs seuils du score BPDAI (Bullous Pemphigoid Disease Area Index) définissant les formes légères, modérées et sévères de la pemphigoïde bulleuse. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
37
|
Metzelard M, Chaby G, Schmidt J, Duhaut P, Boulu X, Clement B, Lombart F, Ikoli J, Chatelain D, Baltazard T, Smail A, Salle V. Association psoriasis et syndrome Sjögren-like : quand la pathologie inflammatoire rencontre la pathologie auto-immune, nouvelle entité ou association fortuite ? Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
38
|
Jelti L, Cordel N, Gillibert A, Lacour JP, Uthurriague C, Doutre MS, Delaporte E, Duvert-Lehembre S, Quereux G, Dupuy A, Adamski H, Bedane C, Misery L, Abasq Thomas C, Fleuret C, Bernard P, Chaby G, D’incan M, Verneuil L, Litrowski N, Joly P. Mortalité du pemphigus et facteurs pronostiques, incluant les traitements initialement proposés. Ann Dermatol Venereol 2018. [DOI: 10.1016/j.annder.2018.09.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
39
|
Joachim C, Gras-Champel V, Marolleau JP, Chaby G, Dairi M, Carmi E. [Cytopenia under topical imiquimod in two patients treated with oral hydroxyurea]. Ann Dermatol Venereol 2018; 145:765-768. [PMID: 30217687 DOI: 10.1016/j.annder.2018.07.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 02/04/2018] [Accepted: 07/30/2018] [Indexed: 11/30/2022]
Abstract
BACKGROUND Aldara® is a topical immunomodulatory treatment. The risks of systemic passage are minimal. There have been rare reports of systemic adverse effects. PATIENTS AND METHODS Case 1. Five sachets weekly of imiquimod were prescribed for Bowen's disease on the forearm in a patient known to have essential thrombocytosis under Hydrea®. His CBC was normal (6000 leukocytes/mm3, 2200 PMN/mm, 230,000 platelets/mm3). Imiquimod was given in 15 sachets weekly. Fifteen day later, the patient presented bicytopenia (3000 leukocytes/mm3, 1400 PMN/mm3, 119,000 platelets/mm3). Hydroxyurea and imiquimod were suspended until normalization of CBC. Hydroxyurea was resumed without recurrence of the bicytopenia. The patient's history included an identical episode following application of imiquimod. Case 2. Five sachets weekly of imiquimod were prescribed for actinic keratosis on the scalp in a patient known to have primary polycythemia under hydroxyurea. Her CBC was normal except for anemia (Hb 11.5g/L, 160,000 platelets/mm3, 1100 lymphocytes/mm3). Imiquimod was given in 12 sachets weekly. Ten days later, anemia increased (Hb 10g/dL) with lymphopenia (800/mm3) and thrombocytopenia (115,000/mm3). Suspension of imiquimod resulted in normalization of the previous CBC values. DISCUSSION . The literature review identified reports of dose-dependent lymphopenia under oral imiquimod but not under Aldara®. The National Pharmacovigilance Database listed 10 cases of hematological disorders most likely caused by Aldara®. Hydroxyurea may induce cytopenia, and while it was not considered the sole causative agent in this case, it is likely to have had a triggering role in these patients with blood dyscrasias. Our findings show that misuse of imiquimod carries a potential risk of hematologic abnormality in patients receiving concomitant hydroxyurea, a commonly combined drug.
Collapse
Affiliation(s)
- C Joachim
- Cabinet de dermatologie, 34, avenue d'Allemagne, 80000 Amiens, France; Service de dermatologie, CHU Amiens-Picardie, site nord, place Victor Pauchet, 80000 Amiens, France.
| | - V Gras-Champel
- Service de pharmacologie clinique, centre régional de pharmacovigilance, CHU d'Amiens-Picardie, 80054 Amiens, France
| | - J-P Marolleau
- Service d'hématologie, CHU d'Amiens-Picardie, 80054 Amiens, France
| | - G Chaby
- Service de dermatologie, CHU Amiens-Picardie, site nord, place Victor Pauchet, 80000 Amiens, France
| | - M Dairi
- Service de dermatologie, CHU Amiens-Picardie, site nord, place Victor Pauchet, 80000 Amiens, France
| | - E Carmi
- Cabinet de dermatologie, 34, avenue d'Allemagne, 80000 Amiens, France
| |
Collapse
|
40
|
Chaby G, Valeyrie-Allanore L, Duong TA, Lebrun-Vignes B, Milpied B, Sassolas B, Tetart F, Wolkenstein P, Chosidow O, Fardet L. Severe cutaneous adverse reactions due to inappropriate medication use. Br J Dermatol 2018; 179:329-336. [PMID: 29352771 DOI: 10.1111/bjd.16365] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/02/2018] [Indexed: 11/29/2022]
Abstract
BACKGROUND The proportion of severe cutaneous adverse reactions (SCARs) that could be avoided if medication use was consistent with good medical practice is unknown. OBJECTIVES To estimate the proportion of SCARs related to inappropriate medication use. METHODS We carried out a retrospective study of all validated SCARs collected in a French registry between 2003 and 2016. For each case, all plausible drugs suspected of inducing SCARs (i.e. not just the drug regarded as 'the most probable') were considered with regard to (i) prescription for an inappropriate indication, (ii) unintentional rechallenge despite a previous allergy to the drug or (iii) self-medication with prescription medicines. RESULTS In total, 602 cases were included in the analyses. Antibiotics, anticonvulsants and allopurinol were the drugs most frequently involved, accounting for more than 50% of all cases. All suspected medications were considered to have been appropriately used for 417 of the 602 individuals included in the study population [69·3%, 95% confidence interval (CI) 65·6-73·0] and inappropriately used for 144 individuals (23·9%, 95% CI 20·5-27·3). These inappropriate uses were due mainly to prescriptions for an inappropriate indication (65·8%, 95% CI 58·4-73·2) or unintentional rechallenge (20·9%, 95% CI 14·6-27·2). Allopurinol and co-trimoxazole were the drugs most frequently involved in inappropriate indications. Antibiotics were the largest group involved in unintentional rechallenge. Nonsteroidal anti-inflammatory drugs, available on prescription, were most frequently involved in inappropriate self-medication. CONCLUSIONS Our results underline the need for respecting the appropriate indication for drugs in order to reduce the incidence of SCARs. Reducing unintentional rechallenge also seems to be a necessary preventive measure.
Collapse
Affiliation(s)
- G Chaby
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France.,Department of Dermatology, Hôpital Nord, Amiens, France
| | | | - T A Duong
- Department of Dermatology, Hôpital Henri-Mondor, AP-HP, Créteil, France
| | - B Lebrun-Vignes
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France.,Department of Pharmacovigilance, Hôpital Pitié-Salpétrière, AP-HP, Paris, France
| | - B Milpied
- Department of Dermatology, Hôpital Saint André, Bordeaux, France
| | - B Sassolas
- Department of Internal Medicine and Pneumology, Hôpital Cavale Blanche, Brest, France
| | - F Tetart
- Deparment of Dermatology, Hôpital Charles Nicole, Rouen, France
| | - P Wolkenstein
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France.,Department of Dermatology, Hôpital Henri-Mondor, AP-HP, Créteil, France
| | - O Chosidow
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France.,Department of Dermatology, Hôpital Henri-Mondor, AP-HP, Créteil, France.,INSERM, Centre d'Investigation Clinique 1430, Créteil, France
| | - L Fardet
- EA 7379 EpiDermE, Université Paris Est Créteil, Créteil, France.,Department of Dermatology, Hôpital Henri-Mondor, AP-HP, Créteil, France
| |
Collapse
|
41
|
Loget J, Saint-Martin C, Guillem P, Kanagaratnam L, Becherel PA, Nassif A, Fougerousse AC, Siham M, Girard C, Barthelemy H, Chaby G, Gabison G, Perrot JL, Pallure V, Beneton N, Boye T, Jacobzone C, Begon E, Bernard P, Reguiai Z. [Misdiagnosis of hidradenitis suppurativa continues to be a major issue. The R-ENS Verneuil study]. Ann Dermatol Venereol 2018; 145:331-338. [PMID: 29704958 DOI: 10.1016/j.annder.2018.01.043] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 11/20/2017] [Accepted: 01/19/2018] [Indexed: 11/25/2022]
Abstract
OBJECTIVE To provide physicians with an understanding of the factors behind significant delays in the diagnosis of hidradenitis suppurativa (HS) in France. PATIENTS AND METHODS This prospective multicentre national study conducted from October 2015 to March 2016 included all patients consulting for HS. Patient data were collected by means of a standardized questionnaire. Univariate and multivariate analyses were conducted to collect factors associated with a significant time to diagnosis of at least 5.5years, defined as the period between the onset of initial clinical signs and the time of formal diagnosis. RESULTS The 16 participating centres enrolled 312 patients (62% women), of average age 35years. The average age at onset of HS was 22years. Before formal diagnosis by a dermatologist (64% of cases), 170 (54%), 114 (37%) and 45 (15%) patients had previously consulted at least 3, 5 and 10 general physicians, respectively. The average time between the initial clinical signs of HS, the first dermatology visit and the definitive diagnosis was 6.2 and 8.4 years, respectively. Active smoking (OR adjusted 1.85; P=0.027) and disease onset at a younger age (adjusted OR 0.92; P<0.001) were both associated with significant delays in diagnosis. CONCLUSION These results emphasized misdiagnosis among HS patients but did not evidence any association between either sociodemographic or economic characteristics and the existence of significant times to diagnosis.
Collapse
Affiliation(s)
- J Loget
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France; ResoVerneuil, France.
| | - C Saint-Martin
- Unité d'aide méthodologique, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - P Guillem
- ResoVerneuil, France; Service de chirurgie adulte, clinique du Val-d'Ouest, 39, chemin de la Vernique, 69130 Ecully, France
| | - L Kanagaratnam
- Unité d'aide méthodologique, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - P-A Becherel
- ResoVerneuil, France; Service de dermatologie, hôpital privé d'Antony, Ramsay générale de santé, 27, avenue de la Providence, 92160 Antony, France
| | - A Nassif
- ResoVerneuil, France; Service de dermatologie, institut Pasteur, 25-28, rue du Dr-Roux, 75015 Paris, France
| | - A-C Fougerousse
- ResoVerneuil, France; Service de dermatologie, hôpital d'instruction des armées Bégin, 69, avenue de Paris, 94160 Saint-Mandé, France
| | - M Siham
- ResoVerneuil, France; Service de dermatologie, hôpital Avicenne, Assistance publique-Hôpitaux de Paris, 125, rue de Stalingrad, 93000 Bobigny, France
| | - C Girard
- ResoVerneuil, France; Service de dermatologie, centre hospitalier universitaire de Montpellier, 191, avenue du Doyen-Gaston-Giraud, 34295 Montpellier cedex, France
| | - H Barthelemy
- ResoVerneuil, France; Cabinet libéral de dermatologie, 2, rue Soufflot, 89000 Auxerre, France
| | - G Chaby
- ResoVerneuil, France; Service de dermatologie, centre hospitalier universitaire Amiens-Picardie site Nord, place Victor-Pauchet, 80054 Amiens cedex 1, France
| | - G Gabison
- ResoVerneuil, France; Cabinet libéral de dermatologie, 32, avenue du Maréchal-de-Lattre-de-Tassigny, 94410 Saint-Maurice, France
| | - J-L Perrot
- ResoVerneuil, France; Service de dermatologie, hôpital Nord, centre hospitalier universitaire de Saint-Étienne, 42055 Saint-Étienne cedex 2, France
| | - V Pallure
- ResoVerneuil, France; Service de dermatologie, centre hospitalier de Perpignan, 20, avenue du Languedoc, 66000 Perpignan, France
| | - N Beneton
- ResoVerneuil, France; Service de dermatologie, centre hospitalier du Mans, 194, avenue Rubillard, 72037 Le Mans, France
| | - T Boye
- ResoVerneuil, France; Service de dermatologie, hôpital d'instruction des armées Sainte-Anne, 2, boulevard Sainte-Anne, 83000 Toulon, France
| | - C Jacobzone
- ResoVerneuil, France; Service de dermatologie, centre hospitalier de Bretagne Sud, 5, avenue de Choiseul, 56322 Lorient cedex, France
| | - E Begon
- ResoVerneuil, France; Service de dermatologie, hôpital René-Dubos, 6, avenue de l'Île-de-France, 95300 Pontoise, France
| | - P Bernard
- Service de dermatologie, hôpital Robert-Debré, CHU de Reims, avenue du Général-Koenig, 51092 Reims cedex, France
| | - Z Reguiai
- ResoVerneuil, France; Service de dermatologie, polyclinique Courlancy, 38 bis, rue de Courlancy, 51100 Reims, France
| | | |
Collapse
|
42
|
Lafabregue E, Denamps J, Chaby G, Lok C. Une pustulose exanthématique aiguë localisée (PEAL) palmo-plantaire. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
43
|
Mahé E, Beauchet A, Fougerousse AC, Becherel PA, Begon E, Chaby G, Bravard P, Quiles-Tsimaratos N, Avenel-Audran M, Poiraud C, Mery-Brossard L, Lons-Danic D, Jacobzone C, Pauwels C, Kupfer-Bessaguet I, Amy de la Breteque M, Maccari F, Sigal ML. Influence des caractéristiques des patients sur le choix d’une biothérapie (anti-TNF-alpha vs anti-Il 12/23) pour un psoriasis. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Chaby G, Valeyrie-Allanore L, Duong TA, Lebrun-Vignes B, Milpied B, Sassolas B, Tetart F, Wolkenstein P, Chosidow O, Fardet L. Toxidermies sévères liées à une prescription inappropriée des médicaments : étude nationale rétrospective. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Plaquevent M, Tetart F, Fardet L, Oro S, Bernard P, Roussel A, Avenel-Audran M, Chaby G, D’incan M, Souteyrand P, Duvert-Lehembre S, Picard-Dahan C, Jeudy G, Labeille B, Morice C, Richard MA, Bourgault Villada I, Litrowski N, Bara C, Mahe E, Prost C, Alexandre M, Quereux G, Soria A, Thomas-Beaulieu D, Pauwels C, Joly P. Pemphigoïdes bulleuses associées aux gliptines : mythe ou réalité ? Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
46
|
Joachim-Naepels C, Dadban A, Arnault JP, Lorriaux A, Denamps J, Lok C, Chaby G. Mésusage médicamenteux : un cas fatal d’érythème pigmenté fixe bulleux généralisé au paracétamol. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Delcroix F, Francois C, Sevestre H, Lok C, Marolleau JP, Chaby G. Étude de la présence et de la signification étiologique d’une réplication cutanée du virus herpès du groupe 6 (HHV6) au cours des exanthèmes en hématologie. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
48
|
Bertrand A, Ofaiche J, Bernard P, Lipsker D, Saillard C, Granel-Brocard F, Jachiet M, Ledard AP, Aubin F, Avenel-Audran M, Chaby G, Jeudy G, Meunier L, Richard MA, Joly P, Guillot B, Dereure O. Place du rituximab dans les pemphigoïdes bulleuse et gestationnelle : étude rétrospective nationale multicentrique de 48 observations. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.09.088] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
49
|
Baltazard T, Dhaille F, Duvert-Lehembre S, Lok C, Chaby G. Trimethoprim-sulfamethoxazole-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Dermatol Online J 2017; 23:13030/qt9gv0j00w. [PMID: 29469749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2017] [Accepted: 08/18/2017] [Indexed: 06/08/2023] Open
Abstract
BACKGROUND Linear IgA bullous dermatosis (LABD) is an autoimmune blistering skin disorder characterized by linear IgA deposits along the dermoepidermal junction. Usually idiopathic, LABD can be drug-induced. OBJECTIVE To report the atypical characteristics of a case of trimethoprim-sulfamethoxazole-induced LABD presenting as toxic epidermal necrolysis (TEN). METHODS A 63-year-old woman treated with trimethoprim-sulfamethoxazole for Pneumocystis jirovecii infection developed a generalized maculopapular rash with herpetiform lesions, rosette-like lesions, and tense bullae with Nikolsky sign. RESULTS Anti-basement membrane zone antibodies were negative, but immunoblot revealed a 160 kDa band corresponding to subepidermal class IgA desmoglein 1. Skin biopsy specimens revealed a subepidermal bulla and direct immunofluorescence showed linear IgA deposition along the basement membrane zone. A diagnosis of toxic epidermal necrolysis was excluded and replaced by trimethoprim-sulfamethoxazole-induced LABD. CONCLUSION We report a case of trimethoprim-sulfamethoxazole-induced LABD with a 160 kDa IgA desmoglein 1 found by immunoblotting analysis, probably by epitope spreading.
Collapse
Affiliation(s)
- T Baltazard
- Department of Dermatology, Hôpital Nord, University of Amiens, Amiens, France.
| | | | | | | | | |
Collapse
|
50
|
Mahé E, Maccari F, Beauchet A, Quiles-Tsimaratos N, Beneton N, Parier J, Barthelemy H, Goujon-Henry C, Chaby G, Thomas-Beaulieu D, Géner G, Wagner L, Pallure V, Devaux S, Vermersch-Langlin A, Pfister P, Jégou J, Livideanu C, Sigal ML. Patients atteints de psoriasis : analyse de la population insatisfaite de sa prise en charge. Ann Dermatol Venereol 2017. [DOI: 10.1016/j.annder.2017.03.025] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|